Open an account

Rebus Holdings

RBSH · OTC

$0.0001−$0.0001 (−50.00%)TodayMarket closed ·
No price history for this range.

About RBSH

Rebus Holdings, Inc. is a pharmaceutical company engaged in the research and development of novel therapeutics for the treatment of cancer. The company is headquartered in Westlake Village, California. The company went IPO on 2009-11-02. The firm is focused on the research and development of targeted precision therapeutics for the treatment of cancer. The firm utilizes its proprietary delivery technology to enhance immuno-modulation for developing therapeutic outcomes. Its immune-oncology lead asset, RT-AR001, is an adenosine A2A receptor antagonist, differentiated by its intratumoral delivery of nano- or microparticle formulations that allow for better tumor infiltration. Its patented portfolio of adenosine receptor antagonists provides treatment based on the specific adenosine targets found in each type of cancer. The adenosine receptor modulators include A2A, A2B and dual A2A/A2B antagonists, that have broad development applicability, including indications within immuno-oncology. The firm is also engaged in the manufacturing of platform delivery systems for nano- or microparticle formulations that are used in toxicology studies.

Employees
0
Headquarters
Westlake Village, California
Listed
Nov 2, 2009
Sector
Health Care
Industry
Biotechnology
Website
inspyrtherapeutics.com

RBSH key statistics

Market cap
3.21K
Price-earnings ratio
0.00
Dividend yield
—
Average volume
899
Volume
1
Open price
$0.0001
High today
$0.0001
Low today
$0.0001
52 Week high
$0.0001
52 Week low
$0.00

Rebus Holdings (RBSH) at a glance

Rebus Holdings (RBSH) last traded at $0.0001, with a market cap of 3.21K and a price-to-earnings ratio of 0.00.

Volume so far is 1 shares, below the average of 899 shares a day.

Over the past year Rebus Holdings has ranged from $0.00 to $0.0001, and now sits 100% of the way up that range.

Rebus Holdings met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q1 FY17 it reported -$25,312.50 per share against an estimate of -$9,753.75.

RBSH earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 20.3% on average.

  1. Q4 FY14: reported -$84,375.00 per share against an estimate of -$86,062.50
  2. Q1 FY15: reported -$101,250.00 per share against an estimate of -$86,062.50
  3. Q2 FY15: reported -$84,375.00 per share against an estimate of -$68,850.00
  4. Q3 FY15: reported -$67,500.00 per share against an estimate of -$68,850.00
  5. Q4 FY15: reported -$67,500.00 per share against an estimate of -$68,850.00
  6. Q1 FY16: reported -$16,875.00 per share against an estimate of -$68,850.00
  7. Q4 FY16: reported -$54,562.50 per share against an estimate of -$48,768.75
  8. Q1 FY17: reported -$25,312.50 per share against an estimate of -$9,753.75

Similar companies

Companies in the same industry as Rebus Holdings

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.